ArticleProceedings of the National Academy of Sciences of the United States of America2023
In vivo three-dimensional brain imaging with chemiluminescence probes in Alzheimer's disease models.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- A Computational Modeling of ADLumin Chemiluminescence: Oxygenation and Dioxetanone Formation.Journal of computational chemistry · 2026Article
- Charge-Based Discrimination of Amyloids Using an Amyloid-Targeting Chemiluminescent Probe.Chembiochem : a European journal of chemical biology · 2026Article
- Highly sensitive chemiluminescence imaging of misfolded proteins in neurodegenerative models.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Amyloid-ID: photocatalytic profiling of amyloid deposits in Alzheimer's disease tissue.Nature communications · 2026Article
- Molecular Afterglow of Lophine-Based Luminophore and Its Imaging Applications.Angewandte Chemie (International ed. in English) · 2025Article
- Unimolecular near-infrared chemiluminescent reporter for cascaded multiplex imaging of ischemia-reperfusion injury in the liver-kidney axis.Nature communications · 2025Article
- HDAC11 displays neuropathological alterations and offers as a novel drug target for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Half-Curcumin-Based Chemiluminescence Probes and Their Applications in Detecting Quasi-Stable Oxidized Proteins.Angewandte Chemie (International ed. in English) · 2024Article
- Development and Evaluation of [ACS omega · 2024Article
- Non-Invasive Device-Mediated Drug Delivery to the Brain across the Blood-Brain Barrier.Pharmaceutics · 2024Article
Corrections and comments
- Update of
Authors and funding
15 authors.
Funding
Abstract
Optical three-dimensional (3D) molecular imaging is highly desirable for providing precise distribution of the target-of-interest in disease models. However, such 3D imaging is still far from wide applications in biomedical research; 3D brain optical molecular imaging, in particular, has rarely been reported. In this report, we designed chemiluminescence probes with high quantum yields, relatively long emission wavelengths, and high signal-to-noise ratios to fulfill the requirements for 3D brain imaging in vivo. With assistance from density-function theory (DFT) computation, we designed ADLumin-Xs by locking up the rotation of the double bond via fusing the furan ring to the phenyl ring. Our results showed that ADLumin-5 had a high quantum yield of chemiluminescence and could bind to amyloid beta (Aβ). Remarkably, ADLumin-5's radiance intensity in brain areas could reach 4 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.